IBDEI0JO ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19827,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,19827,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,19827,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,19828,0)
 ;;=C82.09^^86^994^64
 ;;^UTILITY(U,$J,358.3,19828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19828,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19828,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,19828,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,19829,0)
 ;;=C82.00^^86^994^65
 ;;^UTILITY(U,$J,358.3,19829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19829,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,19829,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,19829,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,19830,0)
 ;;=C82.19^^86^994^66
 ;;^UTILITY(U,$J,358.3,19830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19830,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19830,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,19830,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,19831,0)
 ;;=C82.10^^86^994^67
 ;;^UTILITY(U,$J,358.3,19831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19831,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,19831,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,19831,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,19832,0)
 ;;=C82.29^^86^994^68
 ;;^UTILITY(U,$J,358.3,19832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19832,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19832,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,19832,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,19833,0)
 ;;=C82.20^^86^994^69
 ;;^UTILITY(U,$J,358.3,19833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19833,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,19833,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,19833,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,19834,0)
 ;;=C82.39^^86^994^70
 ;;^UTILITY(U,$J,358.3,19834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19834,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19834,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,19834,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,19835,0)
 ;;=C82.30^^86^994^71
 ;;^UTILITY(U,$J,358.3,19835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19835,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,19835,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,19835,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,19836,0)
 ;;=C82.49^^86^994^72
 ;;^UTILITY(U,$J,358.3,19836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19836,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19836,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,19836,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,19837,0)
 ;;=C82.40^^86^994^73
 ;;^UTILITY(U,$J,358.3,19837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19837,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,19837,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,19837,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,19838,0)
 ;;=C82.99^^86^994^74
 ;;^UTILITY(U,$J,358.3,19838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19838,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19838,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,19838,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,19839,0)
 ;;=C82.90^^86^994^75
 ;;^UTILITY(U,$J,358.3,19839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19839,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,19839,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,19839,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,19840,0)
 ;;=R59.1^^86^994^60
 ;;^UTILITY(U,$J,358.3,19840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19840,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,19840,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,19840,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,19841,0)
 ;;=C91.40^^86^994^79
 ;;^UTILITY(U,$J,358.3,19841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19841,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,19841,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,19841,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,19842,0)
 ;;=C91.42^^86^994^77
 ;;^UTILITY(U,$J,358.3,19842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19842,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,19842,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,19842,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,19843,0)
 ;;=C91.41^^86^994^78
 ;;^UTILITY(U,$J,358.3,19843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19843,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,19843,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,19843,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,19844,0)
 ;;=D57.01^^86^994^80
 ;;^UTILITY(U,$J,358.3,19844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19844,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,19844,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,19844,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,19845,0)
 ;;=D57.00^^86^994^81
 ;;^UTILITY(U,$J,358.3,19845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19845,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,19845,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,19845,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,19846,0)
 ;;=D57.02^^86^994^82
 ;;^UTILITY(U,$J,358.3,19846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19846,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,19846,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,19846,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,19847,0)
 ;;=D68.32^^86^994^84
 ;;^UTILITY(U,$J,358.3,19847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19847,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,19847,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,19847,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,19848,0)
 ;;=C22.2^^86^994^85
 ;;^UTILITY(U,$J,358.3,19848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19848,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,19848,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,19848,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,19849,0)
 ;;=D58.9^^86^994^87
 ;;^UTILITY(U,$J,358.3,19849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19849,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,19849,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,19849,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,19850,0)
 ;;=C81.99^^86^994^88
 ;;^UTILITY(U,$J,358.3,19850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19850,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19850,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,19850,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,19851,0)
 ;;=C81.90^^86^994^89
 ;;^UTILITY(U,$J,358.3,19851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19851,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,19851,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,19851,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,19852,0)
 ;;=D89.2^^86^994^90
 ;;^UTILITY(U,$J,358.3,19852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19852,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,19852,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,19852,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,19853,0)
 ;;=D05.12^^86^994^91
 ;;^UTILITY(U,$J,358.3,19853,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19853,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,19853,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,19853,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,19854,0)
 ;;=D05.11^^86^994^92
 ;;^UTILITY(U,$J,358.3,19854,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19854,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
